[Evaluation of cancer-induced bone diseases by bone metabolic marker].
Recently, several new bone metabolic markers have been developed and applied for diagnosis of bone metastasis. We have investigated the efficacy of several bone metabolic markers : serum carboxy-terminal telopeptide of type 1 collagen ( I CTP), C-terminal cross-linked telopeptide of type I collagen (CTX) and urinary free deoxypyridinoline (fDPD) as bone resorption markers, serum carboxy-terminal propeptide of type 1 collagen (P I CP), osteocalcin (OC), and bone alkaline phosphatase (BAP) as bone formation markers for diagnosis of bone metastasis. I CTP was most useful for diagnosis of bone metastasis in breast cancer patients because of no increase in postmenopausal osteoporosis. Combination of resorption and formation markers increased sensitivity. In follow-up, bone metabolic markers seemed more useful for predicting therapeutic response of bone metastasis than tumor markers. Bone metabolic markers were also useful for predicting survival or occurrence of skeletal-related events. These findings suggest that bone metabolic markers would be useful to detect, to monitor, and to predict prognosis of bone metastases.
Japanese Foundation for Cancer Research, Cancer Institute Hospital, Department of Medical Oncology.
Shunji
S
Takahashi
D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D014408:Biomarkers, Tumor / Q000097:blood* / Q000652:urine; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D001862:Bone Resorption; D024042:Collagen Type I / Q000097:blood; D006801:Humans; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D011379:Prognosis
D000596:Amino Acids; D014408:Biomarkers, Tumor; D024042:Collagen Type I; D010446:Peptide Fragments; D011347:Procollagen; C042813:procollagen type I carboxy terminal peptide; D015675:Osteocalcin; C036020:deoxypyridinoline; D000469:Alkaline Phosphatase